Literature DB >> 25084692

Frequency of recovery and relapse in patients with nonischemic dilated cardiomyopathy on guideline-directed medical therapy.

Ankur Gupta1, Puneet Goyal1, Ajay Bahl2.   

Abstract

Several key clinical questions, such as which patients with dilated cardiomyopathy (DC) will recover, how many will relapse, when will they relapse, and predictors of relapse, have sparse data. The present study examines the frequency and predictors of recovery and relapse in patients with DC. One hundred eighty-eight patients of a nonischemic DC cohort having baseline left ventricular ejection fraction (LVEF) ≤ 40% were divided into 3 groups: improved group with sustained recovery of LVEF to >40% with a net increase in LVEF of ≥ 10% from baseline, not-improved group without change or decrease in LVEF compared with that in baseline including patients with an increase in LVEF <10%, and relapsed group with decrease in LVEF ≥ 10% after initial improvement. Follow-up duration was 50 ± 31 months. One hundred ten patients (59%) did not improve. Of the 78 patients (41%) who improved, 50 (64%) had sustained improvement. Remaining 28 (36%) of the 78 improved patients relapsed on further follow-up of 36 ± 25 months. Baseline LVEF was similar in the 3 groups. Mean LVEF increased from 29 ± 8% to 50 ± 7% (p <0.001) in the improved group, changed from 27 ± 9% to 25 ± 9% (p = 0.95) in the not-improved group, and, after increasing from 30 ± 7% to 52 ± 6%, it decreased to 34 ± 9% (p <0.001) in the relapsed group. Multivariate analysis showed that the only variable associated with recovery of LVEF was shorter QRS duration (odds ratio 0.31, 95% confidence interval 0.15 to 0.67, p = 0.003). Recurrence of left ventricular systolic dysfunction was associated with long QRS duration (odds ratio 3.52, 95% confidence interval 1.27 to 9.76, p = 0.01). In conclusion, with currently recommended medical therapy, 1/4 of patients with nonischemic DC have sustained improvement, and >1/3 of those who improve relapse. QRS duration predicted both recovery and relapse. The survival rate of patients in the improved group was significantly better than that in the other 2 groups (p = 0.03, log-rank).
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 25084692     DOI: 10.1016/j.amjcard.2014.06.021

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  11 in total

1.  Cardiac fibrosis detected by magnetic resonance imaging on predicting time course diversity of left ventricular reverse remodeling in patients with idiopathic dilated cardiomyopathy.

Authors:  Yuki Ikeda; Takayuki Inomata; Teppei Fujita; Yuichiro Iida; Takeru Nabeta; Shunsuke Ishii; Emi Maekawa; Tomoyoshi Yanagisawa; Tomohiro Mizutani; Takashi Naruke; Toshimi Koitabashi; Ichiro Takeuchi; Junya Ako
Journal:  Heart Vessels       Date:  2016-02-03       Impact factor: 2.037

2.  Risk Stratification in Nonischemic Dilated Cardiomyopathy in the Era of Personalized Medicine: Can Cardiac Magnetic Resonance With Late Gadolinium Imaging "Enhance" Our Strategy?

Authors:  Michael Salerno; Austin A Robinson
Journal:  JACC Cardiovasc Imaging       Date:  2018-09

3.  Fifteen-year mortality and prognostic factors in patients with dilated cardiomyopathy: persistent standardized application of drug therapy and strengthened management may bring about encouraging change in an aging society.

Authors:  Xiao-Rong Xu; Meng-Meng Han; Yi-Zhen Yang; Xin Wang; Dong-Yan Hou; Xian-Chen Meng; Hua Wang; Wen-Shu Zhao; Lin Zhang; Lin Xu
Journal:  J Geriatr Cardiol       Date:  2022-05-28       Impact factor: 3.189

4.  Very long-term follow-up data of non-ischemic idiopathic dilated cardiomyopathy after beta-blocker therapy: recurrence of left ventricular dysfunction and predictive value of 123I-metaiodobenzylguanidine scintigraphy.

Authors:  Shunsuke Nishimura; Chisato Izumi; Yoshihiro Himura; Maiko Kuroda; Masashi Amano; Takeshi Harita; Suguru Nishiuchi; Jiro Sakamoto; Yodo Tamaki; Soichiro Enomoto; Makoto Miyake; Toshihiro Tamura; Hirokazu Kondo; Yoshihisa Nakagawa
Journal:  Heart Vessels       Date:  2018-08-24       Impact factor: 2.037

5.  [Predictive factors of left ventricular reverse remodeling in patients with idiopathic or secondary dilated cardiomyopathy].

Authors:  Han Cai; Zhoufei Fang; Zhiyuan Weng; Xueqing Jin
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2018-01-30

6.  Comparison of clinical outcomes in peripartum cardiomyopathy and age-matched dilated cardiomyopathy: A 15-year nationwide population-based study in Asia.

Authors:  Cheng-Hui Lu; Wen-Chen Lee; Michael Wu; Shao-Wei Chen; Jih-Kai Yeh; Chun-Wen Cheng; Katie Pei-Hsuan Wu; Ming-Shien Wen; Tien-Hsing Chen; Victor Chien-Chia Wu
Journal:  Medicine (Baltimore)       Date:  2017-05       Impact factor: 1.889

7.  Long-term outcomes of non-ischemic dilated cardiomyopathy patients with left ventricular ejection fraction ≤19% on medical therapy.

Authors:  Sourabh Agstam; Ajay Bahl; Rohit Manoj Kumar
Journal:  Indian Heart J       Date:  2020-07-21

8.  Strain parameters for predicting the prognosis of non-ischemic dilated cardiomyopathy using cardiovascular magnetic resonance tissue feature tracking.

Authors:  Chengjie Gao; Yajie Gao; Jingyu Hang; Meng Wei; Jingbo Li; Qing Wan; Yijing Tao; Hao Wu; Zhili Xia; Chengxing Shen; Jingwei Pan
Journal:  J Cardiovasc Magn Reson       Date:  2021-03-15       Impact factor: 5.364

Review 9.  Role of Targeted Therapy in Dilated Cardiomyopathy: The Challenging Road Toward a Personalized Approach.

Authors:  Job A J Verdonschot; Mark R Hazebroek; James S Ware; Sanjay K Prasad; Stephane R B Heymans
Journal:  J Am Heart Assoc       Date:  2019-06-01       Impact factor: 5.501

10.  Late gadolinium enhancement for re-worsening left ventricular ejection fraction in patients with dilated cardiomyopathy.

Authors:  Takeru Nabeta; Shunsuke Ishii; Yuki Ikeda; Kenji Maemura; Takumi Oki; Mayu Yazaki; Teppei Fujita; Takashi Naruke; Takayuki Inomata; Junya Ako
Journal:  ESC Heart Fail       Date:  2020-12-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.